A novel budesonide orodispersible tablet with a special esophageal-targeting can induce complete clinical, endoscopic and histologic remission in active Eosinophilic Esophagitis: Results from a post-hoc analysis of the randomized, double-blind, placebo-controlled EOS-1 trial

Stephan Miehlke  1     Christoph Schlag  2     Alex Straumann  3     Michael Vieth  4     Ralph Mueller  5     Roland Greinwald  5     Alfredo J. Lucendo  6    
1 Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany
2 Technische Universität München,München,Germany
3 Swiss EoE Research Network,Olten,Switzerland
4 Klinikum Bayreuth Abt. Pathology,Bayreuth,Germany
5 Dr. Falk Pharma GmbH,Freiburg,Germany
6 Hospit

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing